Early pharmacodynamic assessment using 18F-fluorodeoxyglucose positron-emission tomography on molecular targeted therapy and cytotoxic chemotherapy for clinical outcome prediction

Clinical Lung Cancer

Volumn 15, Issue 3, 2014, Pages 182-187

  Kanazu, Masaki ^a   Maruyama, Kaoru ^b   Ando, Masahiko ^c   Asami, Kazuhiro ^a   Ishii, Mari ^d   Uehira, Kazutaka ^a   Minomo, Shojiro ^a   Matsuda, Yoshinobu ^a   Kawaguchi, Tomoya ^a   Atagi, Shinji ^a   Ogawa, Yoji ^e   Kusunoki, Yoko ^e   Takada, Minoru ^f   Kubo, Akihito ^g  

^a NATIONAL HOSPITAL ORGANIZATION KINKI CHUO CHEST MEDICAL CENTER   (Japan)

^b HYOGO COLLEGE OF MEDICINE   (Japan)

^c NAGOYA UNIVERSITY HOSPITAL   (Japan)

^d YOKOHAMA MUNICIPAL CITIZEN'S HOSPITAL   (Japan)

^e Hanwa Daini Senboku Hospital   (Japan)

^f Koyo Hospital   (Japan)

^g AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cytotoxic chemotherapy; Epidermal growth factor receptor tyrosine kinase inhibitor; Gefitinib; Molecular targeted therapy; Non small cell lung cancer

Indexed keywords

CARBOPLATIN; FLUORODEOXYGLUCOSE F 18; GEFITINIB; PACLITAXEL; ANTINEOPLASTIC AGENT; QUINAZOLINE DERIVATIVE; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ANATOMY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; CYTOTOXIC CHEMOTHERAPY; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; METABOLISM; MOLECULARLY TARGETED THERAPY; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PROGRESSION FREE SURVIVAL; REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR VOLUME; CARCINOMA, NON-SMALL-CELL LUNG; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC USE; DISEASE FREE SURVIVAL; LUNG NEOPLASMS; MIDDLE AGED; PATHOLOGY; PROCEDURES; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; PACLITAXEL; POSITRON-EMISSION TOMOGRAPHY; QUINAZOLINES; RADIOPHARMACEUTICALS; TREATMENT OUTCOME;

EID: 84898013440     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2014.01.001     Document Type: Note

References (38)

1. A. Jemal, R. Siegel, J. Xu, and E. Ward Cancer statistics, 2010 CA Cancer J Clin 60 2010 277 300
2. S.G. Spiro, and G.A. Silvestri One hundred years of lung cancer Am J Respir Crit Care Med 172 2005 523 529 (Pubitemid 41232963)
3. G.V. Scagliotti, F. De Marinis, and M. Rinaldi et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer J Clin Oncol 20 2002 4285 4291 (Pubitemid 35266288)
4. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
5. 18F-FDG PET in patients with non-small-cell lung cancer J Nucl Med 48 2007 1592 1598 (Pubitemid 47572705)
6. M.P. Mac Manus, R.J. Hicks, and J.P. Matthews et al. Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer J Clin Oncol 21 2003 1285 1292 (Pubitemid 46606405)
7. W.A. Weber, V. Petersen, and B. Schmidt et al. Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use J Clin Oncol 21 2003 2651 2657 (Pubitemid 46606307)
8. T.J. Lynch, D.W. Bell, and R. Sordella et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2004 2129 2139 (Pubitemid 38637993)
9. H. Su, C. Bodenstein, and R.A. Dumont et al. Monitoring tumor glucose utilization by positron emission tomography for the prediction of treatment response to epidermal growth factor receptor kinase inhibitors Clin Cancer Res 12 2006 5659 5667 (Pubitemid 44629592)
10. R.M. Pieterman, J.W. van Putten, and J.J. Meuzelaar et al. Preoperative staging of non-small-cell lung cancer with positron-emission tomography N Engl J Med 343 2000 254 267
11. D. Lardinois, W. Weder, and T.F. Hany et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography N Engl J Med 348 2003 2500 2507 (Pubitemid 36706537)
12. 18F] FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol 19 2001 414 419 (Pubitemid 32112853)
13. M. Schulte, D. Brecht-Krauss, and M. Werner et al. Evaluation of neoadjuvant therapy response of osteogenic sarcoma using FDG-PET J Nucl Med 40 1999 1637 1643 (Pubitemid 29471153)
14. R.L. Wahl, K. Zasadny, and M. Helvie et al. Metabolic monitoring of breast cancer chemohormotherapy using positron emission tomography: initial evaluation J Clin Oncol 11 1993 2101 2111 (Pubitemid 23332245)
15. T. Jansson, J.E. Westlin, and H. Ahlstrom et al. Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: a method for early therapy evaluation? J Clin Oncol 13 1995 1470 1477
16. 18Ffluorodeoxyglucose for monitoring primary chemotherapy in breast cancer J Clin Oncol 18 2000 1689 1695 (Pubitemid 30220547)
17. 18F-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy J Clin Oncol 18 2000 1676 1688 (Pubitemid 30220546)
18. 18F-fluoro-2-deoxy- glucose uptake predicts clinical outcome in patients with gefitinib-treated non-small-cell lung cancer Clin Cancer Res 14 2008 2036 2041
19. Y. Satoh, H. Onishi, and A. Nambu et al. Volume-based parameters measured by using FDG PET/CT in patients with stage I NSCLC treated with stereotactic body radiation therapy: prognostic value Radiology 270 2014 275 281
20. 18F- FDG PET/CT predict survival in patients with stage III non-small-cell lung cancer Eur J Nucl Med Mol Imaging 41 2014 50 58
21. A. Kubo, Y. Koh, and T. Hori et al. Pharmacokinetic, pharmacodynamic, and phase II study of gefitinib in patients with malignant pleural effusion from non-small cell lung cancer J Clin Oncol 28 2010 (abstract 3096)
22. A. Kubo, Y. Koh, and T. Kawaguchi et al. Malignant pleural effusion from lung adenocarcinoma treated by gefitinib Intern Med 50 2011 745 748
23. 18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group Eur J Cancer 35 1999 1773 1782 (Pubitemid 29512308)
24. 18F] fluorothymidine positron emission tomography J Clin Oncol 29 2011 1701 1708
25. 18F]fluorodeoxyglucose positron emission tomography at two days of gefitinib treatment predicts clinical outcome in patients with adenocarcinoma of the lung Clin Cancer Res 18 2012 220 228
26. 18F-FDG PET/CT as a potential screening tool in identifying a subgroup of patients with advanced non-small cell lung cancer for immediate maintenance therapy after first-line chemotherapy Eur J Nucl Med Mol Imaging 40 2013 1005 1013
27. J. Amann, S. Kalyankrishna, and P.P. Massion et al. Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer Cancer Res 65 2005 226 235 (Pubitemid 40070814)
28. J.A. Engelman, P.A. Janne, and C. Mermel et al. ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines Proc Natl Acad Sci U S A 102 2005 3788 3793 (Pubitemid 40354690)
29. M.L. Janmaat, F.A. Kruyt, J.A. Rodriguez, and G. Giaccone Response to epidermal growth factor receptor inhibitors in non-small-cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways Clin Cancer Res 9 2003 2316 2326 (Pubitemid 36687658)
30. E. Hajduch, G.J. Litherland, and H.S. Hundal Protein kinase B (PKB/Akt)-a key regulator of glucose transport? FEBS Lett 492 2001 199 203 (Pubitemid 32217828)
31. K. Barnes, E. McIntosh, and A.D. Whetton et al. Chronic myeloid leukaemia: an investigation into the role of Bcr-Abl-induced abnormalities in glucose transport regulation Oncogene 24 2005 3257 3267 (Pubitemid 40695107)
32. C. Cullinane, D.S. Dorow, and M. Kansara et al. An in vivo tumor model exploiting metabolic response as a biomarker for targeted drug development Cancer Res 65 2005 9633 9636 (Pubitemid 41541437)
33. 18F-fluorothymidine PET responses to pharmacologic inhibition of the c-MET receptor in preclinical tumor models J Nucl Med 52 2011 1261 1267
34. S.H. Ou, L. Bazhenova, and D.R. Camidqe et al. Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small-cell lung cancer J Thorac Oncol 5 2010 2044 2046
35. S.H. Ou, E.L. Kwak, and C. Siwak-Tapp et al. Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification J Thorac Oncol 6 2011 942 946
36. U. Haberkorn, I. Morr, and F. Oberdorfer et al. Fluorodeoxyglucose uptake in vitro: aspects of method and effects of treatment with gemcitabine J Nucl Med 35 1994 1842 1850 (Pubitemid 24346810)
37. S.P. Singh, Y. Gao, and L.D. Singh et al. Role of microtubules in glucose uptake by C6 glioma cells Pharmacol Toxicol 83 1998 83 89 (Pubitemid 28419390)
38. T. Egawa-Takata, H. Endo, and M. Fujita et al. Early reduction of glucose uptake after cisplatin treatment is a marker of cisplatin sensitivity in ovarian cancer Cancer Sci 101 2010 2171 2178